Phoenix Financial Ltd. Sells 11,340 Shares of Boston Scientific Corporation $BSX

Phoenix Financial Ltd. lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 14.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,968 shares of the medical equipment provider’s stock after selling 11,340 shares during the quarter. Phoenix Financial Ltd.’s holdings in Boston Scientific were worth $6,194,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after acquiring an additional 111,826 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Boston Scientific by 0.9% during the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after acquiring an additional 128,188 shares in the last quarter. Amundi raised its holdings in shares of Boston Scientific by 17.5% during the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after acquiring an additional 1,781,830 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Boston Scientific by 4.6% during the third quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock valued at $1,020,934,000 after acquiring an additional 463,889 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.0%

NYSE BSX opened at $53.61 on Friday. The stock has a market cap of $79.67 billion, a P/E ratio of 22.43, a P/E/G ratio of 0.97 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $52.75 and a 12 month high of $109.50. The stock’s fifty day moving average price is $63.79 and its 200-day moving average price is $82.00.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific is being highlighted for strong international growth, with APAC momentum, FARAPULSE adoption, and new approvals in Europe and China helping expand its global footprint. Here’s How Boston Scientific Is Expanding Its Global Growth
• Positive Sentiment: Jim Cramer said he would “hold” BSX, implying he sees the company as a stock investors may want to keep rather than sell, which can help sentiment. Jim Cramer on Boston Scientific: “I Think You Gotta Hold It”
• Positive Sentiment: Recent commentary continues to point to Boston Scientific’s cardiovascular franchise as a long-term growth driver, with products like FARAPULSE and WATCHMAN supporting demand. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: The company treated its first patient with Seismiq IVL in the ELEGANCE registry, a small but positive clinical/commercial update that adds to its product pipeline narrative. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and approved governance changes, which may help align incentives but also adds dilution/watch-list considerations for investors. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Negative Sentiment: Some reports say BSX has fallen amid concerns that its growth may not be durable, which likely weighed on sentiment. Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability
• Negative Sentiment: Insiders reportedly sold about $1.2 million of shares, which can signal caution and add to investor concern during a weak stretch for the stock. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: MarketWatch noted that Boston Scientific underperformed peers, reinforcing the view that investor sentiment remains cautious despite the company’s long-term growth story. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BSX shares. National Bank Financial set a $115.00 target price on Boston Scientific in a report on Monday, February 2nd. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday. Argus raised Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Barclays reduced their price target on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Finally, Wells Fargo & Company reduced their price target on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.